Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

Share Price is delayed by 15 minutes
Get Live Data
85.10    0.40 (0.47%)
Bid:
84.70
Ask:
85.30
Spread: 0.60 (0.708%)
Market Cap: £238.45m
ESNT Live PriceLast checked at - London Stock Exchange

Intraday Essentra Share Chart

Directorate change

Today 07:00

RNS Number : 3780I
Essentra plc
16 June 2026
 

ESSENTRA PLC

("Essentra" or the "Company")

 

BOARD APPOINTMENT - NON-EXECUTIVE DIRECTOR

Essentra plc, a leading global manufacturer and provider of essential components and solutions, is pleased to announce the appointment of Sharmila Nebhrajani OBE to the Board of Directors as an independent Non-Executive Director with effect from 29 June 2026. Sharmila will serve on the Audit and Risk, Remuneration, Nomination and ESG Committees and will succeed Mary Reilly as Chair of the Audit and Risk Committee and Senior Independent Director on 1 January 2027. Mary will retire as a director on 31 December of this year.

Sharmila has extensive Board and committee chair experience, gained in a variety of roles spanning the private and public sectors as well as not for profit organisations. A chartered accountant, she began her career in strategy consulting and brings insight from a wide range of sectors, including health, utilities, the media and financial services.

In her executive career, Sharmila spent 13 years at the BBC, latterly as Chief Operating Officer for BBC Future Media and Technology where she managed the business functions of bbc.co.uk including the launch of iPlayer and was most recently Chief Executive at Wilton Park, an executive agency of the UK's Foreign and Commonwealth Office convening international policy dialogues on critical geopolitical issues in global health, defence and diplomacy.

Her current non-executive appointments are Halma plc where she is Audit Committee Chair, Severn Trent plc where she is Chair of the Remuneration Committee and ITV plc. She is also the Chairman of National Institute for Health and Care Excellence (NICE) and a director of Genomics England.

Sharmila studied Medicine at the University of Oxford, is a World Fellow at the University of Yale and was appointed OBE in 2014 for services to medical research.

Steve Good, Essentra Chair, commented:

"We are delighted to have secured Sharmila's extensive experience in a number of sectors which will make a major contribution to the Board and Company and support our growth strategy." 

Sharmila commented:

 

"I look forward to working with Steve and the Essentra Board to help drive growth and to create value for all stakeholders."

 

At the date of this announcement, Sharmila has no interest in the ordinary shares in Essentra plc.

 

This announcement is made pursuant to Listing Rule 6.4.6R. There are no other details required to be disclosed under Listing Rule 6.4.8R.

For further information please contact:

Essentra plc

Scott Fawcett, Chief Executive

Tel: +44 (0)1908 359100

 

 

FTI Consulting

Richard Mountain

Ariadna Peretz

FTI_essentra@fticonsulting.com

Tel: +44 (0)20 3727 1340

 

 

 

 

Notes to Editors

About Essentra plc

Essentra plc is a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra's global network extends to 28 countries worldwide and includes c.3,000 employees, 14 manufacturing facilities, 25 distribution centres and 35 sales & service centres serving c.76,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy. For further information, please visit www.essentraplc.com

LEI: 5493007MOZNA03BVNE96

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFAMFTMTABBMF
Date   Source Headline
16th Jun 20267:00 amRNSDirectorate change
10th Jun 20269:47 amRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:32 pmRNSTransaction in Own Shares
21st May 202610:55 amRNSResult of AGM
20th May 20267:00 amRNSAcquisition of Boteco Srl
20th May 20267:00 amRNS2026 AGM Trading Update
14th May 20265:15 pmRNSDirector/PDMR Shareholding
12th May 20267:03 amRNSTransaction in Own Shares
1st May 202612:17 pmRNSTotal Voting Rights
29th Apr 20268:12 amRNSTransaction in Own Shares
28th Apr 20263:25 pmRNSDirector/PDMR Shareholding
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20268:15 amRNSTransaction in Own Shares
21st Apr 20264:09 pmRNSDirector/PDMR Shareholding
17th Apr 20267:52 amRNSHolding(s) in Company
15th Apr 202610:06 amRNSDirector/PDMR Shareholding
15th Apr 20268:24 amRNSTransaction in Own Shares
15th Apr 20268:18 amRNSHolding(s) in Company
9th Apr 20268:24 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSHolding(s) in Company
1st Apr 20264:45 pmRNSDirector/PDMR Shareholding
1st Apr 20263:21 pmRNSDirector/PDMR Shareholding
1st Apr 20263:15 pmRNSTransaction in Own Shares
1st Apr 20263:08 pmRNSTotal Voting Rights
30th Mar 20262:00 pmRNSAnnual Financial Report
24th Mar 202610:05 amRNSTransaction in Own Shares
24th Mar 20268:17 amRNSHolding(s) in Company
19th Mar 20268:43 amRNSDirector/PDMR Shareholding
17th Mar 20261:41 pmRNSDirector/PDMR Shareholding
17th Mar 202610:30 amRNSDirectorate change
17th Mar 202610:28 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
16th Mar 20269:40 amRNSTransaction in Own Shares
16th Mar 20269:40 amRNSTransaction in Own Shares
13th Mar 202612:00 pmRNSCompany Secretary Change
9th Mar 20269:00 amRNSNotice of Full Year 2025 Results
9th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:58 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 202612:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.